AstraZeneca, Lilly & J&J: Strategic Moves Powering SGLT‐2 Investments | SGLT‐2 Inhibitors Market Forecast 2025-2032

SGLT-2 Inhibitors Market reached US$ 17.95 billion in 2024 and is expected to reach US$ 36.39 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033.

The SGLT-2 Inhibitors Market is extensively analyzed in the latest study by DataM Intelligence, delivering a well-rounded assessment backed by reliable statistics, historical data, and strategic insights. This report profiles leading industry players, examining their product offerings, pricing strategies, financial health, and growth initiatives. It offers a clear perspective on market dynamics, competitive landscape, and emerging trends that are set to shape the industry's future.

Unlock exclusive insights with our detailed sample report (Please enter your Corporate Email ID to get priority access):- https://datamintelligence.com/download-sample/sglt-2-inhibitors-market?rk

SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitors are a class of oral antidiabetic drugs that help lower blood sugar levels in people with type 2 diabetes by preventing the kidneys from reabsorbing glucose back into the blood. Instead, glucose is excreted through urine. These inhibitors also demonstrate cardiovascular and renal benefits, expanding their use beyond glycemic control.

The SGLT-2 inhibitors market includes the development, manufacturing, distribution, and commercialization of these drugs, and is witnessing strong growth due to increasing diabetes prevalence, cardiovascular risk reduction claims, and expanding regulatory approvals.

List of the Key Players in the SGLT-2 Inhibitors Market:

TheracosBio, LLC, Johnson & Johnson Services, Inc., AstraZeneca, Boehringer Ingelheim International GmbH., Eli Lilly and Company., Pfizer Inc., Merck & Co., Inc., and Lexicon Pharmaceuticals, Inc.

SGLT-2 Inhibitors Industry Development:

In June 2024, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) had approved Farxiga (dapagliflozin) for improving glycaemic control in pediatric patients aged 10 years and older with type 2 diabetes (T2D). Previously, the medication had been approved in the U.S. for adults with T2D as an adjunct to diet and exercise to help manage blood sugar levels.

FDA Approval for Broader Indications: In 2024, the FDA approved empagliflozin (Jardiance) for chronic kidney disease (CKD) treatment, following positive results from the EMPA-KIDNEY trial.

Rising Combination Therapies: Growing adoption of SGLT-2 + GLP-1 combinations for synergistic glucose control and weight management is shaping future therapeutic strategies.

Asia-Pacific Market Expansion: China and India have emerged as major markets, driven by increasing diabetes cases and government health initiatives.

New Entrants and Pipeline Drugs: Companies like AstraZeneca, Boehringer Ingelheim, and Merck are expanding their SGLT-2 product pipelines beyond diabetes to include heart failure and non-diabetic kidney disease.

Focus on Cardiometabolic Benefits: Clinical studies have reinforced SGLT-2 inhibitors' role in reducing hospitalization for heart failure and renal deterioration, prompting their adoption in cardiology practice.

Research Methodology

Our research methodology combines both qualitative and quantitative approaches to provide you with a thorough market analysis. We begin by gathering data from trusted industry reports and databases (secondary research), followed by primary research through surveys and interviews with key experts. We then apply advanced statistical tools to analyze the data, uncover trends, and assess market dynamics. Additionally, we use market segmentation and Porter's Five Forces analysis to evaluate competition. This approach ensures that the insights we provide are reliable, actionable, and tailored to support your decision-making process.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/sglt-2-inhibitors-market

Segment Covered in the SGLT-2 Inhibitors Market:

By Drug Type: Bexagliflozin, Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Sotagliflozin.

By Indication: Type-2 Diabetes, Chronic Kidney Disease (CKD), Heart Failure.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, Market Access, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Regional Analysis for SGLT-2 Inhibitors Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of SGLT-2 Inhibitors market?

➠ Who are the global key manufacturers of the SGLT-2 Inhibitors Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the SGLT-2 Inhibitors market opportunities and threats faced by the vendors in the global SGLT-2 Inhibitors Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the SGLT-2 Inhibitors market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription

Contact Us -

Company Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.